DOCSLIB.ORG

Consumer Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Consumer Information IMPORTANT: PLEASE READ Current pregnancy (after 28 weeks of pregnancy) PART III CONSUMER INFORMATION Currently breastfeeding (or planning to breastfeed) Pr Sandoz-Diclofenac Allergy (hypersensitivity) to diclofenac Pr Sandoz-Diclofenac SR sodium, or ASA (Acetylsalicylic Acid) or other (diclofenac sodium) NSAIDs (Nonsteroidal Anti- Inflammatory Drugs), or any of the nonmedicinal ingredients Read this information each time you refill your in Sandoz-Diclofenac or Sandoz-Diclofenac prescription in case new information has been SR added. Ulcer (active) Bleeding or perforation from the stomach or This leaflet is Part III of a three-part "Product gut (active) Monograph" published when PrSandoz-Diclofenac Inflammatory bowel disease (Crohn’s Disease and PrSandoz-Diclofenac SR were approved for or Ulcerative Colitis) sale in Canada and is designed specifically for Liver disease (active or severe) Consumers. This leaflet is a summary and will Kidney problems (severe or worsening) NOT tell you everything about Sandoz-Diclofenac High potassium in the blood or Sandoz-Diclofenac SR. Contact your doctor or pharmacist if you have any questions about the Do not use Sandoz-Diclofenac suppositories if you drug. have inflammation of the rectum or anus or have a recent history of bleeding from the rectum or anus. ABOUT THIS MEDICATION Patients who took a drug in the same class as What the Medication is used for: Sandoz-Diclofenac and Sandoz-Diclofenac SR after a type of heart surgery (coronary artery bypass Your health care provider has prescribed Sandoz- grafting (CABG)) were more likely to have heart Diclofenac or Sandoz-Diclofenac SR for you to relieve attacks, strokes, blood clots in the leg(s) or lung(s), pain and swelling in rheumatoid arthritis and and infections or other complications than those osteoarthritis, including degenerative joint disease of who did NOT take that drug. the hip. Sandoz-Diclofenac and Sandoz-Diclofenac SR should What it does: NOT be used in patients under 16 years of age since the safety and effectiveness have NOT been Sandoz-Diclofenac and Sandoz-Diclofenac SR established. (diclofenac sodium), as nonsteroidal anti- inflammatory drugs (NSAIDs), can reduce the What the medicinal ingredient is: chemicals prostaglandins produced by your body which cause pain and swelling. diclofenac sodium. Sandoz-Diclofenac and Sandoz-Diclofenac SR, as What the non-medicinal ingredients are: nonsteroidal anti-inflammatory drugs (NSAIDs) do NOT cure your illness or prevent it from getting worse. The enteric coated 50 mg tablets (Sandoz Diclofenac) Sandoz-Diclofenac or Sandoz-Diclofenac SR can only contain black ink, castor oil derivatives, colloidal relieve pain and reduce swelling as long as you silicon dioxide, corn starch, hypromellose, iron continue to take it. oxides, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, sodium When it should not be used: starch glycolate, talc, titanium dioxide. DO NOT TAKE Sandoz-Diclofenac or Sandoz- The slow-release 75 mg and 100 mg tablets (Sandoz- Diclofenac SR if you have any of the following Diclofenac SR) contain black ink, carnauba wax, conditions: cellulose compounds, cetyl alcohol, colloidal silicon Heart bypass surgery (planning to have or dioxide, hypromellose magnesium stearate, recently had) polysorbate 80, povidone, red iron oxide, sucrose, talc, Severe, uncontrolled heart failure titanium dioxide. Bleeding in the brain or other bleeding disorders Sandoz-Diclofenac and Sandoz-Diclofenac SR Page 35 of 40 IMPORTANT: PLEASE READ The 50 mg and 100 mg suppositories contain semi- Before taking this medication, tell your health care synthetic glycerides. provider if you have any of the following: What dosage forms it comes in: Disease of the heart or blood vessels (also called cardiovascular disease, including uncontrolled Sandoz-Diclofenac 50 mg (enteric-coated) tablet: light high blood pressure, congestive heart failure, brown, round, S on one side and 50 on the other. established ischemic heart disease, or peripheral arterial disease), as treatment with Sandoz- Sandoz Diclofenac 75 mg Slow Release (SR) tablet: Diclofenac and Sandoz-Diclofenac SR in these light pink, triangular, SR 75 on one side and plain on cases is not recommended. the other. Risk factors for cardiovascular disease (see above) such as high blood pressure, abnormally high Sandoz-Diclofenac 100 mg Slow Release (SR) tablet: levels of fat (cholesterol, triglycerides) in your pink, round, SR 100 on one side and plain on the other. blood, diabetes, or if you smoke. Diabetes mellitus or on a low sugar diet Sandoz-Diclofenac 50 mg and 100 mg Suppositories: Atherosclerosis Bullet shaped, white to yellowish-white colour, with a Poor circulation to your extremities smooth surface with a fat like odour. Kidney disease or urine problems Previous ulcer or bleeding from the stomach or gut Check with your pharmacist if the identifying If you recently had a surgery of the stomach or markings or colour appear different. intestinal tract (intestines, colon, rectum, anus) Previous bleeding in the brain WARNINGS AND PRECAUTIONS Bleeding problems Family history of allergy to NSAIDs, such as If you have, or previously had, any of the acetylsalicylic acid (ASA), celecoxib, diclofenac, following conditions, see your health care diflunisal, etodolac, fenoprofen, flurbiprofen, provider to discuss treatment options other ibuprofen, indomethacin, ketoprofen, ketorolac, than Sandoz-Diclofenac or Sandoz-Diclofenac mefenamic acid, meloxicam, nabumetone, SR: naproxen, oxaprozin, piroxicam, rofecoxib, • Heart Attack or Angina sulindac, tenoxicam, tiaprofenic acid, tolmetin, or • Stroke or Mini-stroke valdecoxib (NOT a complete list) • Loss of Vision Family history of asthma, nasal polyps, long-term • Current Pregnancy (less than 28 weeks) swelling of the sinus (chronic sinusitis) or hives • Congestive Heart Failure High blood pressure Also, before taking this medication, tell your health Diabetes care provider if you are pregnant or you are planning High levels of fats in your blood to get pregnant. Smoking While taking this medication: It is important to take the lowest dose of Tell any other doctor, dentist, pharmacist or other Sandoz-Diclofenac and Sandoz-Diclofenac SR health care professional that you see, that you are that relieves your pain and/or swelling and for taking this medication, especially if you are the shortest time possible in order to keep your planning to have heart surgery, or surgery of the risk of side effects on the heart and blood stomach or intestinal tract; vessels as small as possible. Do NOT drink alcoholic beverages while taking this medication because you would be more likely Use of NSAIDS, such as Sandoz-Diclofenac and to develop stomach problems; Sandoz-Diclofenac SR can result in increased Fertility may be decreased. The use of Sandoz- blood pressure and /or worsening of congestive Diclofenac or Sandoz-Diclofenac SR is not heart failure. recommended in women trying to get pregnant. In women who have difficulty conceiving, stopping Use of NSAIDs, such as Sandoz-Diclofenac and Sandoz-Diclofenac or Sandoz-Diclofenac SR Sandoz-Diclofenac SR, may cause stomach and should be considered. bowel problems (such as ulceration, If you have cardiovascular disease or risks for perforation, obstruction and bleeding). cardiovascular disease, your doctor will periodically re-evaluate whether you should Sandoz-Diclofenac and Sandoz-Diclofenac SR Page 36 of 40 IMPORTANT: PLEASE READ continue treatment with Sandoz-Diclofenac or Diuretics (medicines used to increase the amount Sandoz-Diclofenac SR. of urine) e.g. furosemide, hydrochlorothiazide Your doctor will monitor your kidney function, Lithium your liver function and your blood count to decide Methotrexate (a medicine used to treat some if Sandoz-Diclofenac or Sandoz-Diclofenac SR kinds of cancer or arthritis) needs to be discontinued or if the dose needs to be Oral hypoglycemics (diabetes medications such changed. as metformin) Phenytoin (a medicine used to treat seizures). If, at any time while taking Sandoz-Diclofenac or Probenecid Sandoz-Diclofenac SR you experience any signs or Quinolone antibacterials (medicines used against symptoms of problems with your heart or blood infection) vessels such as chest pain, shortness of breath, Rifampin (an antibiotic medicine used to treat weakness, or slurring of speech, contact your doctor bacterial infections) immediately. Sulfinpyrazone (a medicine used to treat gout) Tacrolimus (a medicine primarily used in patients Long-term use of Sandoz-Diclofenac or Sandoz- who have received organ transplants) Diclofenac SR might increase the risk of heart Trimethoprim (a medicine used to prevent or treat attacks or strokes. urinary tract infection) Voriconazole (a medicine used to treat fungal Sandoz-Diclofenac or Sandoz-Diclofenac SR is infections) NOT recommended for use in patients under 16 years of age since safety and effectiveness have Your health care provider may prescribe low dose NOT been established. ASA (acetylsalicylic acid) as a blood thinner to reduce your risk of having a heart attack or stroke while you INTERACTIONS WITH THIS MEDICATION are taking Sandoz-Diclofenac or Sandoz-Diclofenac SR. Take only the amount of ASA prescribed by your What About Taking Other Drugs At The Same health care provider. You are more likely to upset or Time? damage your stomach if you take both Sandoz- Diclofenac or Sandoz-Diclofenac SR and ASA than if See your health
Load more

Recommended publications
  • Sulfinpyrazone 100Mg and 200Mg Tablets (Sulfinpyrazone)
    Prescribing information sulfinpyrazone 100mg and 200mg tablets (sulfinpyrazone) Presentation: Coated tablets agents, sulphonamides, penicillin, theophylline, phenytoin, non- indication: Chronic, including tophaceous gout; recurrent gouty steroidal antirheumatic drugs. arthritis; hyperuricaemia Pregnancy and lactation: Used with caution in pregnant women, Dosage and administration: Route of administration: Oral. Adults: weighing the potential risk against the possible benefits. It is not known 100-200mg daily increasing gradually (over the first two or three whether the active substance or its metabolite(s) pass into breast milk. weeks) to 600mg daily (rarely 800mg), and maintained until the For safety reasons mothers should refrain from taking the drug. serum urate level has fallen within the normal range. Maintenance Undesirable effects: Mild transient gastro-intestinal upsets, such dose may be as low as 200mg daily. Children: Paediatric usage as nausea, vomiting, diarrhea, gastro-intestinal bleeding and not established. ulcers, acute renal failure, salt and water retention, allergic skin contraindications: Acute attacks of gout. Gastric and duodenal reactions, leucopenia, thrombocytopenia, agranulocytosis, aplastic ulcer. Known hypersensitivity to sulfinpyrazone and other pyrazolone anaemia, hepatic dysfunction, jaundice and hepatitis. derivatives. Contra-indicated in patients with asthma, urticaria, or (Please refer to the Summary of Product Characteristics for acute rhinitis, severe parenchymal lesions of the liver or kidneys, detailed information) porphyria, blood dyscrasias, haemorrhagic diatheses overdose: Nausea, vomiting, abdominal pains, diarrhoea, Precautions and warnings: Used with caution in patients with hypotension, cardiac arrhythmias, hyperventilation, respiratory hyperuricaemia or gout, episodes of urolithiasis or renal colic, disorders, impairment of consciousness, coma, epileptic seizures, ensure adequate fluid intake and alkalinisation of the urine during oliguria or anuria, acute renal failure, renal colic.
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1 PRODUCT NAME DICLOFENAC SANDOZ 25mg enteric coated tablet 50mg enteric coated tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Diclofenac Sandoz 25 mg tablet contains Diclofenac Sodium 25mg Each Diclofenac Sandoz 50 mg tablet contains Diclofenac Sodium 50mg Tablets contain lactose. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM 25 mg Brown-yellow gastro-resistant film coated tablets, round, biconvex faced with a plain rim. Approximate tablet dimensions: diameter 6.1 to 6.3 mm; thickness 2.9 to 3.2 mm. Each tablet contains Diclofenac Sodium Ph Eur 25 mg. 50 mg Brown-yellow gastro-resistant film coated tablets, round, biconvex faced with a banded rim. Approximate tablet dimensions: diameter 8.0 to 8.3 mm; thickness 3.5 to 3.8 mm. Each tablet contains Diclofenac Sodium Ph Eur 50 mg. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of: • Inflammatory and degenerative forms of rheumatism - rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism; • Acute attacks of gout; • Post-traumatic and post-operative pain, inflammation, and swelling, e.g. following dental or orthopaedic surgery; • Painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis; • As an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. In keeping with general therapeutic principles, the underlying Page 1 of 18 NEW ZEALAND DATA SHEET disease should be treated with basic therapy, as appropriate. Fever alone is not an indication. 4.2 Dose and method of administration Dosage Diclofenac Sandoz should only be prescribed when the benefits are considered to outweigh the potential risks.
    [Show full text]
  • Nonsteroidal Antiinflammatory Drugs and Acute Renal Failure in Elderly Persons
    American Journal of Epidemiology Vol. 151, No. 5 Copyright © 2000 by The Johns Hopkins University School of Hygiene and Public Health Printed In U.S.A. Ail rights reserved Nonsteroidal Antiinflammatory Drugs and Acute Renal Failure in Elderly Persons Marie R. Griffin,1'2 Aida Yared,3 and Wayne A. Ray1 Renal prostaglandin inhibition by nonsteroidal antiinflammatory drugs (NSAIDs) may decrease renal function, Downloaded from https://academic.oup.com/aje/article/151/5/488/117194 by guest on 27 September 2021 especially under conditions of low effective circulating volume. To evaluate the risk of important deterioration of renal function due to this effect, the authors performed a nested case-control study using Tennessee Medicaid enrollees aged £65 years in 1987-1991. Cases were patients who had been hospitalized with community- acquired acute renal failure; they were selected on the basis of medical record review of Medicaid enrollees with selected discharge diagnoses. Information on the timing, duration, and dose of prescription NSAIDs used, demographic factors, and comorbidity was gathered from computerized Medicaid-Medicare data files. Of the 1,799 patients with acute renal failure (4.51 hospitalizations per 1,000 person-years), 18.1% were current users of prescription NSAIDs as compared with 11.3% of 9,899 randomly selected population controls. After control for demographic factors and comorbidity, use of NSAIDs increased the risk of acute renal failure 58% (adjusted odds ratio = 1.58; 95% confidence interval (Cl): 1.34, 1.86). For ibuprofen, which accounted for 35% of NSAID use, odds ratios associated with dosages of £1,200 mg/day, >1,200-<2,400 mg/day, and £2,400 mg/day were 0.94 (95% Cl: 0.58, 1.51), 1.89 (95% Cl: 1.34, 2.67), and 2.32 (95% Cl: 1.45, 3.71), respectively (test for linear trend: p = 0.009).
    [Show full text]
  • WO 2010/099522 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 September 2010 (02.09.2010) WO 2010/099522 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/4164 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/4045 (2006.01) A61K 31/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2010/025725 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 1 March 2010 (01 .03.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/156,129 27 February 2009 (27.02.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, HELSINN THERAPEUTICS (U.S.), INC.
    [Show full text]
  • S Salsalate Tablets
    SALSALATE TABLETS CARDIOVASCULAR EFFECTS renal disease. If SALSALATE TABLETS therapy must be initiated, Rx Only Cardiovascular Thrombotic Events close monitoring of the patient’s renal function is advisable. Cardiovascular Risk Clinical trials of several COX-2 selective and nonselective NSAIDs Anaphylactoid Reactions • NSAIDs may cause an increased risk of serious cardiovascular of up to three years duration have shown an increased risk of As with other NSAIDs, anaphylactoid reactions may occur in thrombotic events, myocardial infarction, and stroke, which can serious cardiovascular (CV) thrombotic events, myocardial patients without known prior exposure to SALSALATE TABLETS. be fatal. This risk may increase with duration of use. Patients infarction, and stroke, which can be fatal. All NSAIDs, both COX-2 SALSALATE TABLETS should not be given to patients with the with cardiovascular disease or risk factors for cardiovascular selective and nonselective, may have a similar risk. Patients with aspirin triad. This symptom complex typically occurs in asthmatic disease may be at greater risk. (See WARNINGS and CLINICAL known CV disease or risk factors for CV disease may be at greater patients who experience rhinitis with or without nasal polyps, or TRIALS). risk. To minimize the potential risk for an adverse CV event in who exhibit severe, potentially fatal bronchospasm after taking • SALSALATE TABLETS is contraindicated for the treatment of patients treated with an NSAID, the lowest effective dose should be aspirin or other NSAIDs (see CONTRAINDICATIONS and perioperative pain in the setting of coronary artery bypass graft used for the shortest duration possible. Physicians and patients PRECAUTIONS - Preexisting Asthma). Emergency help should be (CABG) surgery (see WARNINGS Gastrointestinal Risk) should remain alert for the development of such events, even in sought in cases where an anaphylactoid reaction occurs.
    [Show full text]
  • Highlights of Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------------CONTRAINDICATIONS-------------------------------------­ These highlights do not include all the information needed to use Patients with known hypersensitivity to natural or recombinant hirudins, IPRIVASK safely and effectively. See full prescribing information for and in patients with active bleeding and/or irreversible coagulation IPRIVASK. disorders (4). IPRIVASK® 15 mg (desirudin for injection), for subcutaneous injection -----------------------WARNINGS AND PRECAUTIONS-----------------------------­ Initial U.S. approval: 2003 • Hemorrhage: Bleeding can occur at any site during therapy with WARNING: SPINAL/EPIDURAL HEMATOMAS Iprivask. An unexplained fall in hematocrit or blood pressure should See Full Prescribing Information for complete boxed warning. lead to a search for a bleeding site. Avoid intramuscular injection as When neuraxial anesthesia (epidural/spinal anesthesia) or local bleeding and hematoma formation may result. (5.3). spinal puncture is employed, patients anticoagulated or • Increased Risk of bleeding with Renal Impairment: Dose reductions scheduled to be anticoagulated with selective inhibitors of by factors of three and nine are recommended for patients with thrombin such as Iprivask may be at risk of developing an moderate and severe renal impairment respectively (2.2). In addition, epidural or spinal hematoma which can result in long-term or daily aPTT and serum creatinine monitoring are recommended for permanent paralysis (5.1). patients with moderate
    [Show full text]
  • Chemmart Meloxicam
    Chemmart Meloxicam Capsules Meloxicam Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet Ask your doctor if you have any swelling of the feet or lips due to questions about why this medicine fluid build-up Read this leaflet carefully before has been prescribed for you. · You experience bleeding from the taking your medicine. Your doctor may have prescribed this stomach, gut or any other This leaflet answers some common medicine for another reason. bleeding questions about meloxicam. It does This medicine is available only with · You have had a stroke resulting not contain all the available a doctor©s prescription. from a bleed in the brain or have information. It does not take the a bleeding disorder place of talking to your doctor or How it works · You currently have a peptic pharmacist. Meloxicam belongs to a family of (stomach) ulcer All medicines have risks and medicines called Non-Steroidal Anti- · You are lactose intolerant (this benefits. Your doctor has weighed inflammatory Drugs (NSAIDs). medicine contains lactose) the risks of you using this medicine These medicines work by relieving · You have Crohn©s Disease or against the benefits they expect it pain and inflammation. Ulcerative Colitis will have for you. There is no evidence that this · You have severe liver or kidney Keep this leaflet with your medicine is addictive. problems medicine. · You are currently taking other You may want to read it again. medicines known as: sulfinpyrazone (used to treat Before you take this gout), fluconazole (used to treat medicine fungal infections) or certain What this medicine is sulfur antibiotics (e.g.
    [Show full text]
  • Information for the User Diclofenac / Omeprazole Modified-Release
    Package Leaflet: Information for the User Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg diclofenac sodium/omeprazole Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, please ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg is and what it is used for 2. What you need to know before you take Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg 3. How to take Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg 4. Possible side effects 5. How to store Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg 6. Contents of the pack and other information 1. What Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg is and what it is used for Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg contains two active ingredients in a single capsule. These active ingredients are diclofenac sodium (75 mg) and omeprazole (20 mg). Diclofenac is one of a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs) and is used to reduce pain and inflammation of joint disorders.
    [Show full text]
  • Gastro-Duodenal Ulcers Associated with the Use of Non-Steroidal Anti-Inflammatory Drugs: a Systematic Review of Preventive Pharmacological Interventions
    Gastro-duodenal Ulcers Associated with the Use of Technology Non-steroidal Anti- inflammatory Drugs: A Systematic Review Report of Preventive Issue 38 September 2003 Pharmacological Interventions Publications can be requested from: CCOHTA 600-865 Carling Avenue Ottawa, Ontario, Canada K1S 5S8 Tel. (613) 226-2553 Fax. (613) 226-5392 Email: [email protected] or download from CCOHTA’s web site: http://www.ccohta.ca Cite as: Rostom A, Dubé C, Jolicoeur E, Boucher M, Joyce J. Gastro-duodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2003. Technology report no 38. Reproduction of this document for non-commercial purposes is permitted provided appropriate credit is given to CCOHTA. CCOHTA is a non-profit organization funded by the federal, provincial and territorial governments. Legal Deposit - 2003 National Library of Canada ISBN: 1-894620-92-5 (print) ISBN: 1-894620-93-3 (electronic version) Publications Mail Agreement Number: 40026386 Canadian Coordinating Office for Health Technology Assessment Gastro-duodenal Ulcers Associated with the Use of Non-steroidal Anti-inflammatory Drugs: A Systematic Review of Preventive Pharmacological Interventions Alaa Rostom MD MSc FRCPC1 1 Catherine Dubé MD MSc FRCPC 1 Emilie Jolicoeur MD 2 Michel Boucher BPharm MSc 2 Janet Joyce MLS September 2003 ________________________ 1 University of Ottawa, Ottawa, Ontario 2 Canadian Coordinating Office for Health Technology Assessment, Ottawa, Ontario Reviewers These individuals kindly provided comments on this report. External Reviewers Isabelle Chabot, PhD Betsy Miller, BScPharm MSc Manager, Health Economics and Executive Director Outcomes Research Patient Access and Outcomes Research Merck Frosst Canada & Co.
    [Show full text]
  • New Zealand Data Sheet IBUPROFEN LIQUID CAPSULES
    New Zealand Data Sheet IBUPROFEN LIQUID CAPSULES Neo Health Ibuprofen liquid capsules 400mg 1 PRODUCT NAME Ibuprofen 400mg Liquid capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains Ibuprofen 400 mg. For full list of excipients, see section 6.1 3.PHARMACEUTICAL FORM Capsule, soft Natural transparent, oval shaped, soft gelatin capsule containing clear colourless liquid. imprinted with L 160 in Black edible ink. 4.CLINICAL PARTICULARS 4.1 Therapeutic indications This medical product is indicated in adults and children & adolescents 12 years of age and over for the symptomatic treatment of mild to moderate pain and/or inflammation associated with headache, migraine, tension headache, muscular pain, dental pain, period pain, sinus pain, back pain, arthritis pain, cold and flu symptoms. 4.2 Dosage and administration For oral use and short-term use only. Capsules should not be chewed. Undesirable effects may be minimized by using the lowest effective dose for the shortest possible duration necessary to control symptoms (see section 4.4) Adults and children & adolescents 12 years of age and over. Initial dose, one capsule with water. Then, if necessary, one capsule every six hours. Do not exceed six capsules (2400 mg) in any 24-hour period. If in children and adolescents between 12 and 18 years this medicinal product is required for 3 days, or if symptoms worsen a doctor should be consulted. If in adults the product is required for more than 3 days in the case of fever and 4 days for treatment of pain, or if the symptoms worsen the patient is advised to consult a doctor.
    [Show full text]
  • Vinblastine and Sulfinpyrazone Export by the Multidrug Resistance Protein MRP2 Is Associated with Glutathione Export
    British Journal of Cancer (2000) 83(3), 375–383 © 2000 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1262, available online at http://www.idealibrary.com on Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export R Evers1,4, M de Haas1, R Sparidans2, J Beijnen2, PR Wielinga3, J Lankelma3 and P Borst1 1Division of Molecular Biology and Center of Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Pharmacy, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands; 3Academic Hospital Vrije Universiteit, Department of Medical Oncology, Room BR232, PO Box 7057, 1007 MB Amsterdam, The Netherlands; 4Present address Georg-Speyer-Haus, Paul Ehrlich straße 42–44, 60596 Frankfurt am, Germany Summary The multidrug resistance proteins MRP1 and MRP2 are members of the same subfamily of ATP-binding cassette transporters. Besides organic molecules conjugated to negatively charged ligands, these proteins also transport cytotoxic drugs for which no negatively charged conjugates are known to exist. In polarized MDCKII cells, MRP1 routes to the lateral plasma membrane, and MRP2 to the apical plasma membrane. In these cells MRP1 transports daunorubicin, and MRP2 vinblastine; both transporters export reduced glutathione (GSH) into the medium. We demonstrate that glutathione transport in MDCKII-MRP1 cells is inhibited by the inhibitors of organic anion transporters sulfinpyrazone, indomethacin, probenecid and benzbromarone. In MDCKII-MRP2 cells, GSH export is stimulated by low concentrations of sulfinpyrazone or indomethacin, whereas export is inhibited down to control levels at high concentrations. We find that unmodified sulfinpyrazone is a substrate for MRP2, also at concentrations where GSH export is inhibited.
    [Show full text]
  • Ibuprofen 600 Mg Film- Coated Tablets
    Package leaflet: Information for the user You should discuss your treatment with your doctor or pharmacist before taking Ibuprofen if Ibuprofen 600 mg film- you: • have heart problems including heart failure, coated tablets angina (chest pain), or if you have had a heart attack, bypass surgery, peripheral Read all of this leaflet carefully before artery disease (poor circulation in the legs you start taking this medicine because it or feet due to narrow or blocked arteries), or contains important information for you. any kind of stroke (including ‘mini-stroke’ or - Keep this leaflet. You may need to read it transient ischaemic attack “TIA”). again. • have high blood pressure, diabetes, high - If you have any further questions, ask your cholesterol, or have a family history of heart doctor or pharmacist. disease or stroke, or if you are a smoker. - This medicine has been prescribed for you Effects on the kidneys only. Do not pass it on to others. It may Ibuprofen may cause problems with kidney harm them, even if their signs of illness are function even in patients who have not had the same as yours. kidney problems before. This may result in - If you get any side effects, talk to your swelling of the legs and may even lead to heart doctor or pharmacist. This includes any failure or high blood pressure in predisposed possible side effects not listed in this leaflet. individuals. See section 4. Ibuprofen may cause kidney damage especially What is in this leaflet in patients who already have kidney, heart or 1. What Ibuprofen is and what it is used for liver problems, or are taking diuretics or ACE 2.
    [Show full text]